Jan 30, 2025 / 02:00PM GMT
Editor
Portions of this transcript marked (technical difficulty) indicate audio problems. The missing text will be supplied if a replay becomes available.
Paul Hudson - Sanofi SA - Chief Executive Officer, Executive Director, Member of the Executive Committee
(technical difficulty) controlling stake in Appellate and further prioritize R&D. On the business, we achieved double digit sales growth with strong contribution from launches.
This included Beyfortus that achieved blockbuster status in its first full year of sales. In R&D, we're pleased with the positive Phase 3 results of fitusiran, rilzabrutinib and tolebrutinib. They provide the foundation for potential launches this year, underpinning our sustainable growth. We are thrilled by the Phase 2 of duvacatode that is ready to move to Phase 3, pending regulatory feedback. Pooman will share more pipeline details later.
Looking at Q4 on slide 6, we reported double digit sales growth for a third consecutive quarter, supported by our key drivers, vaccines, Dupixent and pharma launches. Taking a
Q4 2024 Sanofi SA Earnings Call Transcript
Jan 30, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers